Design considerations for randomized comparisons of neoadjuvant-adjuvant versus adjuvant-only cancer immunotherapy when tumor measurement schedules do not align (SWOG S1801)

By sjmartinez • March 19, 2025

Othus M, Sharon E, Wu MC, Sondak VK, Ribas A, Patel SP. Design considerations for randomized comparisons of neoadjuvant-adjuvant versus adjuvant-only cancer immunotherapy when tumor measurement schedules do not align (SWOG S1801). Clin Trials. 2025 Mar 18:17407745251321371. doi: 10.1177/17407745251321371. Epub ahead of print. PMID: 40099861.

Tags: Hematology/Oncology, neoadjuvant, Publications, Randomized comparison, tumor measurement schedule

Lenvatinib plus pembrolizumab versus standard of care in recurrent/metastatic head and neck squamous cell carcinoma: Randomized, phase 2 LEAP-009 trial

Kim HR, Oliva M, Salas S, Wong DJ, Even C, Kim JW, Kang M, Wu SY, Lauche O, Ahn MJ, Yang MH, Lien MY, Metcalf[...]

Late Recognition of Glucose-6-Phosphate Dehydrogenase Deficiency in a 70-Year-Old Man: A Case Report

Huynh J, Eisenbud L, Gutierrez R, Chuang FL, Dichter D. Late Recognition of Glucose-6-Phosphate Dehydrogenase Deficiency in a 70-Year-Old Man: A Case Report. Cureus. 2026[...]

Resistance to Immune Checkpoint Inhibitor Treatment in Non-Small Cell Lung Cancer Clinical Trials: A Perspective From Lung-MAP Investigators

Doroshow DB, Leal TA, Waqar SN, Borghaei H, Camidge DR, Dragnev KH, Edelman MJ, Gandara DR, Gerber DE, Gray JE, Hirsch FR, Husain H, Kozono[...]